IMRIS Stock Rating Lowered by Zacks (IMRS)
IMRIS (NASDAQ:IMRS) was downgraded by Zacks to a “neutral” rating in a research report issued on Wednesday, AnalystRatingsNetwork.com reports. They currently have a $1.80 target price on the stock. Zacks‘ price objective would indicate a potential upside of 2.86% from the company’s current price.
IMRS has been the subject of a number of other recent research reports. Analysts at Cowen and Company initiated coverage on shares of IMRIS (NASDAQ:IMRS) in a research note to investors on Friday, August 30th. They set an “outperform” rating and a $3.50 price target on the stock. Separately, analysts at RBC Capital cut their price target on shares of IMRIS (NASDAQ:IMRS) from $4.00 to $3.00 in a research note to investors on Tuesday, August 20th. They now have a “sector perform” rating on the stock. Finally, analysts at Canaccord Genuity cut their price target on shares of IMRIS (NASDAQ:IMRS) from C$5.00 to C$4.00 in a research note to investors on Wednesday, August 14th. They now have a “buy” rating on the stock.
Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. IMRIS presently has an average rating of “Buy” and a consensus target price of $3.26.
IMRIS (NASDAQ:IMRS) traded up 1.71% during mid-day trading on Wednesday, hitting $1.78. The stock had a trading volume of 77,065 shares. IMRIS has a 52-week low of $1.75 and a 52-week high of $4.75. The stock has a 50-day moving average of $2.49 and a 200-day moving average of $2.83. The company’s market cap is $92.4 million.
IMRIS (NASDAQ:IMRS) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.16) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.16). The company had revenue of $10.23 million for the quarter, compared to the consensus estimate of $10.12 million. Analysts expect that IMRIS will post $-0.59 EPS for the current fiscal year.
IMRIS Inc (NASDAQ:IMRS) designs, manufactures and markets the VISIUS Surgical Theatre, a multifunctional surgical environment that provides intraoperative vision to clinicians.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.